Back to Search
Start Over
Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA-Ven) or liposomal daunorubicin-cytarabine (CPX-351).
- Source :
-
American journal of hematology [Am J Hematol] 2021 Jun 01; Vol. 96 (6), pp. E196-E200. Date of Electronic Publication: 2021 Apr 08. - Publication Year :
- 2021
- Subjects :
- Adult
Aged
Bridged Bicyclo Compounds, Heterocyclic administration & dosage
Combined Modality Therapy
Cytarabine administration & dosage
Daunorubicin administration & dosage
Female
Hematopoietic Stem Cell Transplantation
Humans
Kaplan-Meier Estimate
Leukemia, Myeloid, Acute mortality
Leukemia, Myeloid, Acute therapy
Liposomes
Male
Middle Aged
Neoplasms, Second Primary mortality
Neoplasms, Second Primary therapy
Remission Induction
Retrospective Studies
Sulfonamides administration & dosage
Treatment Outcome
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Leukemia, Myeloid, Acute drug therapy
Neoplasms, Second Primary drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1096-8652
- Volume :
- 96
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- American journal of hematology
- Publication Type :
- Editorial & Opinion
- Accession number :
- 33719090
- Full Text :
- https://doi.org/10.1002/ajh.26157